Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2022-01-21 4:01 pm Sale |
2021-12-31 | 13G | Chinook Therapeutics, Inc. KDNY |
ATP Life Science Ventures L.P. | 0 0.000% |
-4,028,937 (Position Closed) |
Filing History |
| 2021-06-28 8:56 pm Sale |
2021-06-21 | 13D | Akero Therapeutics, Inc. AKRO |
ATP Life Science Ventures L.P. | 674,640 1.900% |
-5,164,229 (-88.45%) |
Filing History |
| 2021-06-28 8:54 pm Sale |
2021-06-21 | 13D | Stoke Therapeutics, Inc. STOK |
ATP Life Science Ventures L.P. | 1,912,256 5.200% |
-15,293,789 (-88.89%) |
Filing History |
| 2020-11-27 4:58 pm Purchase |
2020-11-20 | 13D | Stoke Therapeutics, Inc. STOK |
ATP Life Science Ventures L.P. | 17,206,045 47.500% |
419,332 (+2.50%) |
Filing History |
| 2020-11-16 4:14 pm Purchase |
2020-10-05 | 13G | Chinook Therapeutics, Inc. KDNY |
ATP Life Science Ventures L.P. | 4,028,937 9.600% |
4,028,937 (New Position) |
Filing History |
| 2020-07-14 5:06 pm Purchase |
2020-07-10 | 13D | Akero Therapeutics, Inc. AKRO |
ATP Life Science Ventures L.P. | 5,838,869 17.200% |
423,666 (+7.82%) |
Filing History |